Results: FGFR aberrations were found in 7.1% of cancers, with the majority being gene amplification (66% of the aberrations), followed by mutations (26%) and rearrangements (8%). FGFR1 (mostly amplification) was affected in 3.5% of 4853 patients; FGFR2, in 1.5%; FGFR3, in 2.0%; and FGFR4, in 0.5%. Almost every type of malignancy examined showed some patients with FGFR aberrations, but the cancers most commonly affected were urothelial (32% FGFR-aberrant); breast (18%); endometrial (~13%), squamous lung cancers (~13%), and ovarian cancer (~9%). Among 35 unique FGFR mutations seen in this dataset, all but two are found in COSMIC. Seventeen of the 35 are known to be activating and 11 are transforming. 
INTRODUCTION
Fibroblast growth factor receptors (FGFRs) are highly conserved, widely distributed transmembrane tyrosine kinase receptors. They are involved in development, differentiation, cell survival, migration, angiogenesis, and carcinogenesis (1) . In humans, there are four such FGFRs that are typical tyrosine kinase receptors (FGFR1-4), and one that lacks an intracellular tyrosine kinase domain (FGFRL1 or FGFR5). There are also 18 human ligands for FGFRs, which are known as fibroblast growth factors (1) .
When FGFs bind to their cognate receptors, the receptors dimerize, leading to intracellular phosphorylation of receptor kinase domains, a cascade of intracellular signaling, and gene transcription (2) . FGF/FGFRs signal through several intracellular pathways, including the Ras/Raf/MEK and the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-Akt pathway (1) . All four FGFRs share structural homology with vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and other tyrosine kinase receptors, which has implications for pharmacologic therapy (2) . Specific FGFR aberrations have been observed in a proportion of certain cancers (e.g., FGFR3
mutations in bladder cancer (3) and FGFR1 amplification in squamous cell lung cancer (4) ). Some of these FGFR abnormalities are likely to be "driver" aberrations. There is also evidence that changes in specific FGFR expression may be related to prognosis or sensitivity to cancer treatments (5) (6) (7) .
Since the majority of FGFR aberrations identified to date lead to gain-of-function, it is reasonable to hypothesize that targeting these cancers with FGFR inhibitors would be therapeutically beneficial (8) . In vitro data suggest that this is indeed the case (9) . Several tyrosine kinase inhibitors (TKIs) have been Author Manuscript Published OnlineFirst on September 15, 2015; DOI: 10.1158/1078-0432.CCR- drug is lenvatinib, which is approved for iodine-refractory, well-differentiated thyroid carcinoma. Other FDA-approved FGFR-inhibiting drugs include regorafenib, approved for advanced colorectal carcinoma and drug-resistant gastrointestinal stromal tumors (GIST), ponatinib, approved for drug-resistant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukemia (ALL), and pazopanib, approved for renal cell carcinoma and sarcoma. None of these are FDA-approved on the basis of targeting FGFR (or any other molecular phenotype). The hypothesis that selecting for FGF/FGFR aberration might increase response rates or other clinical benefits is being tested in several ongoing trials that require FGF/FGFR aberrations for eligibility. These and other clinical trials will shed light on the specific patient populations that would benefit from FGFR-inhibiting drugs and possibly on specific molecular aberrations that predict response to these drugs.
In fact, it is highly likely that optimizing the clinical utility of FGFR-targeting therapies will depend on appropriate selection of patient populations. To that end, developing a clear understanding of the landscape of FGFR aberrations in various cancer types is relevant and necessary for more effective use of these pharmaceutical agents. Next-generation sequencing technology makes rapid and accurate identification of these aberrations feasible. Herein, we describe the landscape of FGFR abnormalities, including mutations, amplifications and rearrangements, in 4853 patient samples from diverse cancers.
Research. 
METHODS
We collected sequencing data from 4853 cancers of various types (specific cancer types and numbers of cases are listed in Supplementary Tables S2 and S3 ) from patients whose formalin-fixed, paraffin-embedded (FFPE) tumor samples were submitted to a CLIA-certified lab for genomic profiling (Foundation Medicine, Cambridge, MA). Samples were required to have a surface area ≥ 25 mm Table S1 ). The samples collected for this study were assayed between December 16, 2011 and November 14, 2013. Sequence data were processed using a customized analysis pipeline (10) . Sequencing was performed with an average sequencing depth of coverage greater than 250x, with > 100x at > 99% of exons. This method of sequencing allows for detection of copy number alterations, gene rearrangements, and somatic mutations with 99% specificity and > 99% sensitivity for base substitutions at ≥ 5 mutant allele frequency and > 95% sensitivity for copy number alterations. A threshold of ≥ 6 copies for gene amplification (except for ERRB2, which is considered amplified with ≥ 5 copies) was used. The submitting physicians provided specification of tumor types. The database was deidentified with only diagnosis available. Next-generation sequencing data were collected and interpreted by N-of-One (Lexington, MA). For this study, the dataset of 4853 sequenced tumors was queried for alterations in FGFR1-4 and co-aberrant genes. Data was analyzed in accordance with UCSD IRB guidelines. Here, we report on the prevalence and frequencies of these aberrations in human cancers.
RESULTS
Of the 4853 cancers sequenced, we observed 360 FGFR aberrations in 343 cases (17 cancers had more than one FGFR alteration), for an overall frequency of 7.1%. FGFR1 alterations were more common than alterations in FGFR2-4 (Figures 1 and 2) . The majority of the FGFR aberrations were gene amplifications (66% of 360 FGFR aberrations), with gene mutations being less common (26%) and gene rearrangements rare (8%) (Figure 2) . These proportions were similar across all four FGFRs (Supplementary Figures S1 to S4) Non-small Cell Lung Cancer (NSCLC): There were 675 cases of NSCLC in the dataset (Figures 2 and 3 , Supplementary Tables S2 and S6 ). There was a marked difference between squamous cell histology (N = 93), adenocarcinoma (N = 408), and other non-small cell types (e.g. large cell carcinoma). In particular, squamous cell lung carcinoma was most notable for its 9% frequency of FGFR1 amplification, which is in contrast to only 4% of lung adenocarcinomas harboring any FGFR abnormality (Figure 3) . PIK3CA. The overall frequency of PIK3CA mutation among urothelial tumors was 20.6% (25 cases, one case had two mutations). Among the 32 urothelial tumors with FGFR3 abnormalities, 6 (24%) had coexisting PIK3CA gene abnormalities, suggesting that combination therapy with anti-FGFR and anti-PIK3CA drugs could be evaluated. The frequencies of aberration in these two genes is likely an independent occurrence (χ2 p-value = 0.86 in this dataset), which is in contrast to two other published studies (15, 16) in which PIK3CA mutation was positively correlated with FGFR aberration. However, it should be noted that in the first study, 77% were stage Ta/T1 and 57% were grade G1/G2, and in the second study 75% were stage Ta/T1 and grade G1/G2, and both studies reported a stronger correlation between PIK3CA and FGFR abnormalities in earlier stage and lower grade tumors. Other genes of interest that were co-aberrant with FGFR3 amplification include CDKN2A (8 cases), TSC1 (5 cases), ARID1A (5 cases), and TP53 (4 cases). To facilitate exploration of co-aberrant genes, we listed all urothelial and other tumor types from our dataset that had any FGFR aberration and all co-existing gene aberrations in Supplementary Table S6 .
We grouped all urothelial carcinomas together for this analysis, though it is possible that there are differences in molecular phenotype according to where in the genitourinary tract the urothelial tumors arise. Among the 126 urothelial cancers we evaluated, 22 of 90 bladder carcinomas, 11 of 21 renal pelvis carcinomas, 3 of 6 ureteral carcinomas, and 4 of 9 urothelial carcinomas not otherwise specified (NOS) had FGFR aberrations. While these data may suggest that FGFR gene aberrations are least frequent among urothelial carcinomas arising from the lower urinary tract, our dataset is not equipped to make this determination because of small numbers of patients in certain subsets. To avoid sample size bias, we chose to analyze only those tumor types with at least 75 representative cases, and bladder is the only site in the urothelial tract that meets this requirement with 90 cases (renal pelvis had 21, urothelial not otherwise specified 9, and ureter 6 cases). FGFR3 mutations seen in urothelial cancers are able to transform NIH-3T3 cells, but have less potent effects on normal bladder cells (TERT-NHUC). These data suggest that FGFR3 mutations may confer a selective proliferative advantage to early urothelial lesions, but that they may also have cell-type specific effects that may explain the observed differences in mutation frequencies among urothelial tumors.
In our dataset, we do not have grade or stage information for any of the tumor samples, including the urothelial tumors. This means that we cannot say whether they are superficial or invasive nor whether they are low-or high-grade tumors. We therefore cannot draw conclusions about the significance of Estrogen receptor and progesterone receptor protein expression are not measured by the NGS assay used.
In contrast, ERBB2 (Her2) amplification of ≥ 5-fold is detected by the assay. Only 4 of 72 breast cancer cases with any FGFR aberrations also had ERBB2 amplification measured in this fashion.
Eighteen percent of breast cancers analyzed had any FGFR aberration, the most common of which was FGFR1 amplification (~14%), while amplification of FGFR2-4 was much less frequent (0.5-2.3%).
Since PIK3CA alterations are among the most commonly seen in breast cancer (17) (18) (19) , it is interesting to note that 26.4% (19/ 22% to 34.5% for hormone receptor positive and Her2 positive breast cancers (17) (18) (19) , perhaps suggesting that there is no relationship to FGFR aberration. In fact, the χ2 p-value = 0.61, so it is very likely that these two genes are independently selected for in the breast cancer cases analyzed.
Other genes of interest that were co-aberrant in the FGFR1-amplified subset of breast cancers include CCND1 amplification (21 cases), MYC amplification (21 cases Tables S2 and S6 ). These cancers include, but are not limited to, ovarian cancer (~9%), gliomas (~8%), pancreatic, renal, colorectal cancer, and neuroendocrine (about 4 to 5% each), and sarcomas (~4%).
SPECIFIC ABERRATIONS AND THEIR FUNCTIONAL SIGNIFICANCE:
Preclinical Work and Implications for Drug Development FGFR1 amplification: FGFR1 amplification is one of the most common FGFR alterations seen in this dataset (Supplementary Figure S1A) . only induces phosphorylation of downstream effectors, but is also capable of transforming NIH3T3 cells in vitro (25) . These data suggest that both of these mutations are likely pathogenic in vivo and represent valid targets for drug development.
FGFR2 has a higher missense mutation rate in our dataset (12 unique mutations, all but one of which are reported in the COSMIC database; see Supplementary Table S4 ). Seven are known to be activating mutations. FGFR2 S252W, P253R, and N549K were the most commonly seen FGFR2 alterations. FGFR2 S252W and P253R lie in the receptor's extracellular linker region between the two immunoglobulin-like domains, a key site for ligand binding (26) , and are thought to differentially increase ligand binding affinity, thereby increasing receptor signaling (27) . Both are also capable of transforming NIH3T3 cells despite the fact that the mutant receptor is expressed at lower levels than the wild-type (26) .
Furthermore, knockdown of the S252W mutant receptor by specific shRNA inhibits both transformation and survival of MFE-280 cells in vivo (26) , strongly suggesting that the FGFR2 S252W mutation and possibly also the P253R mutation are compelling targets for drug therapy. The FGFR2 N549 residue is associated with a "molecular brake" that keeps the kinase in an auto-inhibited state (28) . The N549K mutation presumably disrupts this inhibition, leading to increased kinase activity. It also transforms NIH3T3 cells (26) . Among the other FGFR2 mutations known to be activating (A315T, Y375C, C382R, and K659E), only C382R and K659E are known to transform NIH3T3 cells (26, 29) . We are unaware of data regarding the transformational ability of the other FGFR2 mutations in our dataset.
FGFR3 also had a high rate of mutation, with 13 unique mutations identified in the dataset (Supplementary Table S4 ). All but one have been reported in the COSMIC database. Eight of them are known to be activating and four of them are able to transform cells in vitro. The most common missense mutations in FGFR3 were S249C (17 cases), R248C (9 cases), G370C (4 cases), K650E (4 cases), R399C receptor basal phosphorylation (30) and leads to anchorage independent growth(31) and xenograft tumors in mice (32) . Furthermore, gene knockdown of this mutant receptor abolishes transformation (33) . The nearby FGFR3 R248C mutation, which is the second most common FGFR3 mutation in our dataset, is similarly activating and transforming. For both of these mutations, the creation of a new, unpaired cysteine residue results in formation of inter-receptor disulfide bones, increased homodimerization and signaling (34) . In vitro, FGFR3 R248C promotes increased cell numbers at confluence, induces proliferation, induces morphological transformation, reduces apoptosis, and decreases attachment to fibronectin, but does not alter migration (34, 35) . FGFR3 G370C lies in the extracellular juxtamembrane region. In 293T cells, it leads to ligand-independent dimerization and phosphorylation (30) . We are unaware of data regarding the ability of this mutation to transform cells in vitro. FGFR K650E also shows ligand independent activation, though by undefined mechanism(s) (35, 36) and is able to transform NIH3T3 cells (37, 38) . FGFR3 Y373C is also thought to induce disulfide bond formation causing constitutive activation of the receptor (32, 35) . It is a strong inducer of transformation, which can be abrogated by siRNA-mediated knockdown or SU5402 (a potent FGFR inhibitor) (32, 37) , suggesting that this mutation represents a valid drug target. We are unaware of data regarding functional significance or transformational ability of FGFR3 R399C.
Among the five unique mutations observed in FGFR4, all were previously reported in the COSMIC database, but to our knowledge none of them have been characterized to date. cholangiocarcinoma, cervical adenocarcinoma, cervical squamous cell carcinoma, endometrial carcinoma, non-small cell lung carcinoma, pancreatic carcinoma, gallbladder carcinoma, renal cell carcinoma, and carcinoma of unknown primary. All gene fusions are listed in Supplementary Table S5 .
Chromosomal translocations in cancers that lead to fusion proteins exert their oncogenic effects through overexpression of an otherwise normal gene or creation of a chimeric gene in which parts of two genes are fused together. In the case of FGFR3-TACC3, the entire FGFR3 kinase domain is fused with the TACC3 domain that mediates microtubule binding (31, 39) . These fusion proteins activate the MAPK pathway when transfected into normal human urothelial cells, suggesting that they retain active signaling. 
DISCUSSION
This study represents a comprehensive overview of FGFR aberrations in a large cancer genomic database. About 7% of cancers had FGFR aberrations, with the most common abnormality being FGFR1 amplification. Overall, 5% of 4853 patients had FGFR amplifications; 2%, mutations; and 0.5%, rearrangements. FGFR1 was affected in 3.5% of 4853 patients; FGFR2, in 1.5%; FGFR3, in 2.0% and FGFR4, in 0.5% (Figure 1) . Almost every histology included individuals who harbored FGFR aberrations, but the cancers most commonly affected were urothelial (32% FGFR-aberrant), breast (18%), endometrial (~13%), squamous cell lung (~13%) (Figure 3) , ovarian (~9%), carcinoma of unknown primary (~8%), glioma (~89%), and cholangiocarcinoma (7%) (Figure 2 and Supplementary Tables S2   and S6 ).
FGFR aberrations did not appear to segregate well by histology. However, some aberrations were found more frequently in certain cancers. For example, FGFR1 amplifications predominated in squamous cell lung, breast, ovarian, and urothelial cancers, observed in 5% to 14% of patients with these malignancies; FGFR3 mutations predominated in bladder and other urothelial tumors, observed in 15% of individuals. Others (20, 21, 40, 41 ) also reported high rates of FGFR1 amplification in squamous cell lung cancer (13-22%). Squamous cell cancers originating in other organs were analyzed together and showed FGFR aberrations in 5.1% of cases (most frequently FGFR1 amplification). There were insufficient small cell lung cancers (43 cases) in our dataset to report.
While therapies targeting the aberrant proteins produced by mutated EGFR or rearranged ALK have been applied successfully in lung adenocarcinoma and the FDA recently approved nivolumab for squamous cell lung carcinoma, no therapy based on molecular phenotype is currently approved for squamous cell or other non-adenocarcinoma types of lung cancers. However, FGFR inhibitors are being developed for NSCLC, including squamous cell carcinomas. For example, the results of at least two phase III clinical trials of the multikinase inhibitor nintedanib (which targets FGFR, VEGFR, and PDGFR) in NSCLC showed statistically significant, albeit modest, benefit (42, 43) . These studies did not Eighteen percent of breast cancers had an FGFR aberration, the most frequent being FGFR1 amplification (14% of cases), while amplification of FGFR2-4 was much less common (0.5-2.3%).
FGFR1 amplification may be a strong independent predictor of overall survival in patients with breast cancer (45) and may also correlate with endocrine therapy resistance(6), suggesting prognostic value for assessing FGFR1 status. It is also possible that patients with FGFR1-amplified breast cancer might benefit from the administration of FGFR inhibitors. In fact, lucitanib, a dual kinase inhibitor (FGFR/VEGFR), has shown activity in FGFR1-amplified breast cancer, with an overall response rate of 50% (46) , and other studies are ongoing.
About 11 percent of endometrial cancers were found to have FGFR abnormalities, mostly activating mutations in or amplification of FGFR2 (~9% of patients). As described above in the Results section, the FGFR2-S252W mutation increases affinity for the FGF ligands, in particular FGF9, which may be especially important for endometrial cancer because it is found in abundance in the endometrial stroma (47) . Also intriguing is that FGFR2 and KRAS mutations seem to be mutually exclusive in endometrial cancers, suggesting redundancy with regard to activation of the MAPK pathway (48) .
We also noted FGFR gene fusions (usually involving FGFR2 or FGFR3) in a minority of the cases. The most common fusion partner was TACC3 (31) , perhaps because FGFR3 and TACC3 are close together on chromosome 4p16 (39) . Fusion of FGFR3 with TACC3 leads to ligand-independent signaling activation in glioblastoma and bladder cancer (31, 39, 49) . Mice harboring FGFR-TACC3-associated gliomas respond to administration of an FGFR inhibitor (39) .
Stratifying by type of abnormality, FGFR1 amplification was one of the most common FGFR anomalies observed (Supplementary Figure S1A) There are some limitations to these data. First, the dataset was not annotated and therefore correlation with clinical characteristics (e.g., stage, phenotype, etc.) was not possible, which may have greater importance for some tumor types than for others (see Urothelial Cancers). Second, the number of patients with each cancer was dependent on the number of cases submitted by physicians for nextgeneration sequencing analysis, which introduces the possibility of sample size bias. Finally, pathologic diagnosis was designated based on the determination of the submitting attending physician/pathologist.
Our observed frequency of primarily activating FGFR aberrations in diverse cancers, along with preclinical and early clinical data already reported suggest that targeting FGFR alterations with cognate inhibitors has therapeutic potential. There is also evidence that there are FGFR alterations that confer resistance to other types of cancer treatment (6, 7) and that some specific FGFR aberrations may demonstrate differential sensitivity/resistance to distinct FGFR inhibitors (50) . Intriguingly, some FGFR2
and FGFR3 somatic mutations were identical to mutations that, in germline form, are associated with dwarfism. However, there are no published epidemiologic data to suggest that individuals with germline FGFR aberrations and dwarfism have an increased incidence of cancer, suggesting that developmental compensatory mechanisms can mitigate the oncogenic potential of these aberrations. FGFR may also have prognostic value. Indeed, in breast cancer, FGFR1 amplification was independently associated with poor survival (45) . Further study will be needed to elucidate the impact of each of the FGFR aberrations on cancer phenotype, prognosis, and response to treatment. Since many FGFR changes appear to activate signaling, it is also important to characterize the clinically relevant effects of the many potent FGFR Table   S4 ). Frequencies are expressed as percentages of all 126 cases. There were 44 aberrations in 40 cases (4 cases had more than one aberration), so the total is greater than 100%.
